Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 15, 2016 16:01 ET | Source: Agios Pharmaceuticals

Agios Provides Update on PKR Program

- Development of Second PKR Activator AG-519 Discontinued Following FDA Feedback - - Lead PKR Activator AG-348 Advancing into Pivotal Development in Pyruvate Kinase Deficiency - - Company...
December 05, 2016 19:30 ET | Source: Agios Pharmaceuticals

Agios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced Hematologic Malignancies

- Overall Response Rate of 38% and Complete Remission Rate of 18% with Patients on Study up to 24.2 Months - - For Relapsed/Refractory Acute Myeloid Leukemia Patients, Overall Response Rate of 33%...
December 04, 2016 19:30 ET | Source: Agios Pharmaceuticals

Agios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency

- AG-348 Is Well-Tolerated and Demonstrates Clinically Relevant, Rapid and Sustained Hemoglobin Increases in 15 of 26 Patients with at Least One Missense Mutation and 15 out of 32 Patients Overall -...
November 18, 2016 07:01 ET | Source: Agios Pharmaceuticals

Agios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma

- Durable Stable Disease Observed for Patients with Non-enhancing Low Grade Glioma and Chondrosarcoma Patients; 42% of Glioma Patients Still on Treatment - - AG-120 Well-tolerated in...
November 03, 2016 09:13 ET | Source: Agios Pharmaceuticals

Agios to Present New Data from PKR and IDH Programs at the 2016 ASH Annual Meeting

- Updated Safety and Efficacy Data from AG-348, AG-519 and Completed Dose Escalation Portion of AG-120 Study to be Highlighted in Oral and Poster Presentations - - Company to Host Investor...
November 03, 2016 07:01 ET | Source: Agios Pharmaceuticals

Agios Reports Third Quarter 2016 Financial Results and Reviews Recent Progress in IDH and PKR Development Programs

– Enasidenib (AG-221) on Track for NDA Submission in IDH2m Positive Relapsed/Refractory AML by Year End – ...
November 01, 2016 07:01 ET | Source: Agios Pharmaceuticals

Agios to Present at the 25th Annual Credit Suisse Healthcare Conference Tuesday, November 8, 2016

CAMBRIDGE, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
October 27, 2016 07:01 ET | Source: Agios Pharmaceuticals

Agios to Webcast Conference Call of Third Quarter 2016 Financial Results on November 3, 2016

CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
September 20, 2016 16:01 ET | Source: Agios Pharmaceuticals

Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

CAMBRIDGE, Mass., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of common stock,...
September 14, 2016 20:14 ET | Source: Agios Pharmaceuticals

Agios Announces Pricing of $150 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 3,370,786 shares of common...